ResMed Stock To Go Ex-dividend Tomorrow (RMD)

The ex-dividend date for ResMed (NYSE:RMD) is tomorrow, May 17, 2013. Owners of shares as of market close today will be eligible for a dividend of 17 cents per share. At a price of $49.64 as of 9:30 a.m., the dividend yield is 1.3%.

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- The ex-dividend date for ResMed (NYSE: RMD) is tomorrow, May 17, 2013. Owners of shares as of market close today will be eligible for a dividend of 17 cents per share. At a price of $49.64 as of 9:30 a.m. ET, the dividend yield is 1.3%.

The average volume for ResMed has been 1.1 million shares per day over the past 30 days. ResMed has a market cap of $7.29 billion and is part of the health care sector and health services industry. Shares are up 21.6% year to date as of the close of trading on Wednesday.

ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. The company has a P/E ratio of 24, above the S&P 500 P/E ratio of 17.7.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full ResMed Ratings Report.